, Volume 27, Issue 5, pp 433–434 | Cite as

The Author’s Reply

  • Lieven Annemans


  1. 1.
    Cleemput I, Thiry N. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium [letter]. Pharmacoeconomics 2009; 27 (5): 433PubMedCrossRefGoogle Scholar
  2. 2.
    Annemans L, Rémy V, Oyee J, et al. Cost-Effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium. Pharmacoeconomics 2009; 27 (3): 231–45PubMedCrossRefGoogle Scholar
  3. 3.
    Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337 (7665): 331–5Google Scholar
  4. 4.
    Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008 Aug 21; 359 (8): 821–32PubMedCrossRefGoogle Scholar
  5. 5.
    Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121 (3): 621–32PubMedCrossRefGoogle Scholar
  6. 6.
    Thiry N, De Laet C, Hulstaert F, et al. Cost effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening. Int J Technol Assess Health Care 2009 Apr; 25 (2): 161–70PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Lieven Annemans
    • 1
  1. 1.Faculty of MedicineGhent University HospitalGhentBelgium

Personalised recommendations